Home » Topics » Regulatory » EMA

EMA
RSS

CHMP adopts positive opinion for oxycodone/naloxone in RLS

Oct. 27, 2014

EMA outlines recent efforts to expedite development of Ebola treatments

Oct. 23, 2014

EMA grants orphan drug designation to Epidiolex for Dravet syndrome

Oct. 22, 2014

EMA grants orphan drug designation to isactuzumab govitecan

Oct. 21, 2014

Lymphoseek recommended by CHMP for sentinel lymph node detection

Sep. 30, 2014

EMA committee recommends approval of Rezolsta, announces darunavir label extensions

Sep. 30, 2014

Boehringer Ingelheim's nintedanib receives positive opinion for second-line therapy of NSCLC

Sep. 29, 2014

Signifor recommended by CHMP to treat patients with acromegaly

Sep. 29, 2014

EMA committee recommends European approval of Cyramza

Sep. 29, 2014

Harvoni recommended for the treatment of chronic hepatitis C

Sep. 29, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...